Esperion Shares Flat at $3.16 as Archimed Bid Nears Endgame
Esperion Therapeutics shares stayed flat at $3.13 late Wednesday, just under Archimed’s $3.16-a-share cash offer. Investors are looking at what’s left in the take-private deal and the open milestone risks. The stock moved in a tight range from $3.13 to $3.14, with volume topping 7 million shares. Esperion isn’t just a small-cap drug name trading on growth anymore. Now it’s more of a merger spread play, with shares moving on the gap between the deal price and where it trades. The spread’s slim, but still there.